Latest Conference Articles

At week 8, significantly more children, adolescents, and adults who applied 1.5% ruxolitinib cream versus vehicle achieved IGA treatment success.

Fred Saad, MD, discussed findings from the phase 3 ARANOTE and ARASENS trials.

The administration of immunotherapy in adjuvant, neoadjuvant, and perioperative settings offers distinct benefits and challenges in resectable cancers, with recent clinical trials highlighting its potential to improve long-term outcomes and the need for further research into biomarkers and combination strategies.

Nadofaragene firadenovec led to most patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer (NMIBC) experiencing a complete response (CR) at 3 months.

The FDA’s accelerated approval of lifileucel (Amtagvi; Iovance Biotherapeutics) marks a major milestone in immunotherapy for metastatic melanoma, building on decades of research in tumor-infiltrating lymphocyte therapy.

Immunotherapy pioneer James P. Allison, PhD, revolutionized cancer treatment by discovering immune checkpoint blockade, leading to significant advances in survival rates and ongoing efforts to optimize immuno-oncology strategies.

Melody Smith, MD, MS, discusses how microbiome modulation may influence CAR T-cell therapy toxicity and outcomes, highlighting potential future interventions and clinical integration challenges.

The AACR Immunotherapy Conference 2025 will provide pharmacists with the opportunity to engage with cutting-edge cancer immunotherapy research, explore advancements in treatments, such as immune checkpoint inhibitors and CAR T-cell therapy, and connect with key leaders in the field.

Melody Smith, MD, MS, discusses how the intestinal microbiome influences CAR T-cell therapy outcomes, highlighting the negative impact of certain antibiotics and the potential role of dietary interventions in improving treatment efficacy.

Nivolumab demonstrated a sustained disease-free survival benefit over placebo in high-risk muscle-invasive urothelial carcinoma (MIUC).

The data were presented at the 2025 ASCO Genitourinary Cancers Symposium.

C. Brooke Adams, PharmD, BCOP, discusses the evolving diagnostic criteria and management strategies for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR T-cell therapy, highlighting advances in toxicity prevention and treatment selection.

Data from the phase 2 CABRAMET trial suggests the potential of cabozantinib for treatment of brain metastases from renal cell carcinoma (RCC).

Enfortumab vedotin, trastuzumab deruxtecan, and disitamab vedotin were highlighted at the 2025 ASCO Genitourinary Cancers Symposium.

Panelists at the 2025 ASCO Genitourinary Cancers Symposium discussed challenges and new approaches to treatment.

The combination of the antibody-drug conjugate and PD-1/L1 inhibitor yielded an improved progression-free survival in locally advanced or metastatic urothelial carcinoma.

The data were presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, California.

The expanding role of real-world evidence in regulatory and health technology assessment (HTA) decision-making highlights its growing acceptance for supplementing clinical trial data, addressing evidence gaps, and informing treatment value, despite challenges in data quality, accessibility, and regulatory compliance.

Andrew Lin, PharmD, BCOP, discusses his pharmacist-led study examining the association between early tacrolimus levels and outcomes post-allogeneic hematopoietic cell transplantation.

The combination greatly improved progression-free survival and overall survival.

Talazoparib in combination with enzalutamide yielded significant improvements in radiographic progression-free survival and overall survival.

Diversity in clinical trials remains important to ensure research data for therapies accurately reflects the diverse patient populations who will use them globally.

Molly Schiffer, PharmD, BCOP, discusses the logistical, operational, and financial challenges of delivering cellular therapies in the outpatient setting, focusing on CAR T-cell therapy, TIL therapies, and emerging trends in non-oncology applications.

J Ryan Shaw, PharmD, BCPS, BCOP, CPP, discusses the value of the ASTCT and CIBMTR Tandem Meeting 2025 as a platform for multidisciplinary collaboration, cutting-edge education, and advancing pharmacy practice in transplant and cellular therapy.

Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, discusses the logistical challenges and interprofessional strategies essential for delivering cellular therapies in outpatient settings, emphasizing the pharmacist's role in improving patient outcomes and addressing health disparities.

Molly Schiffer, PharmD, BCOP, discusses the logistical and operational challenges of delivering outpatient CAR T-cell therapy, emphasizing the benefits of outpatient treatment, including reduced costs, improved access to therapy, and better quality of life for patients.

Africa's unparalleled genetic diversity presents both a challenge and an opportunity to advance precision medicine, with a focus on leveraging pharmacogenetics to improve drug efficacy and reduce adverse reactions.

Catriona Jamieson, MD, PhD, discusses the role of stress-activated base editors like ADAR1p150 and APOBEC enzymes in cancer progression and highlights innovative approaches to halt these processes and improve therapeutic outcomes.

γδ T cells are emerging as a transformative immunotherapy approach in oncology, offering unique mechanisms for targeting hematologic and solid tumors, with clinical trials demonstrating promising survival outcomes and durable immune responses.

Edward Kim, MD, MBA, discusses critical points of patient leakage in precision medicine, emphasizing the role of multidisciplinary teams in streamlining care, managing medications, and improving patient outcomes.